The current research focus of The Laboratory of Translational Genetics is to discover and validate new biomarkers for early detection, prediction of disease course and outcome and treatment response in cancer, in particular breast and ovarian cancers. Each year thousands of women die from these types of cancer which may have been prevented if methods of early detection and more effective treatments were available.
Biomarkers of Breast and Ovarian Cancer
The team has been studying the presence and levels of biomarkers such as microRNAs (miRNAs) in diseases. MiRNAs are small (19-25nt), noncoding RNAs that regulate gene expression post-transcriptionally by binding in the 3’ untranslated region (3’UTR) of their specific messenger RNAs and interfering with translation. They are involved in normal cellular development, differentiation and proliferation. However, dysregulation of miRNA expression can have a causal role in malignancies. The presence and expression levels of specific tissue miRNAs have been associated with different types of cancer and clinical outcome. MiRNAs are remarkably stable and are well preserved in formalin fixed, paraffin embedded tissue samples and have been detected in plasma and serum samples, making them ideal candidates for non-invasive biomarkers of disease.
In 2012, over 20,000 new cases of ovarian cancer will be diagnosed and over 15,000 women will die of the disease. It is the 5th leading cause of cancer deaths in women. Only 1 in 5 women are diagnosed with early stage ovarian cancer when 5 year survival rates greater than 90% can be achieved. The majority of ovarian cancer cases are not diagnosed until it has spread to other organs at which time 5 year survival is less than 30%. Currently, ovarian cancer can only be diagnosed through invasive surgery to remove the ovaries. Less than 1 in 15 surgeries identifies cancerous ovarian tumors; the remaining surgeries remove benign ovarian cysts.
In a pilot study of 60 women with confirmed ovarian cancer, they identified 15 miRNAs that had different levels in blood compared to women without ovarian cancer. The availability of a blood test to specifically and accurately detect ovarian cancer would provide a noninvasive method for early detection and give women the opportunity to have treatment when it’s the most effective and the cancer is potentially curable. Currently no blood test to detect early stage ovarian cancer exists. In addition, this type of blood test would avoid unnecessary risks and complications associated with surgeries to remove benign cysts that were suspected of being cancerous.
The contributions of this research extend far beyond ovarian cancer detection alone. There are two main directions of current research 1) Circulating ovarian cancer specific miRNAs are most likely present at lower levels before a solid tumor mass is formed. These biomarkers may identify women who are at high risk of developing ovarian cancer. 2) Since the main role of miRNA is to regulate normal cellular functions, by identifying which miRNAs are being expressed inappropriately, the team will know which cellular pathways are affected by ovarian cancer. This type of information is important for developing new therapies aimed at prevention and curative approaches.
The mortality rates due to ovarian cancer have largely remained unchanged since “the war on cancer” was initiated more than 40 years ago. Although more advanced chemotherapy treatments are available, they are most effective when used during the optimal treatment period of early stage disease, before the cancer has metastasized to other parts of the body. Currently only 20% of ovarian cancers are detected in the early stage, while 80% go undetected and progress to advanced stage disease. By identifying circulating blood biomarkers that accurately detect the presence of early ovarian cancer, more women will have the opportunity for treatment when the curable rate can potentially approach 100%.
The American Cancer Society estimates there will be 226, 870 new cases of breast cancer diagnosed in 2012 and 39,510 women will die of the disease in the US.It is the leading cause of death in American women between the ages of 30 and 50. Breast cancer accounts for over 15% of all cancer related deaths in the US.
To explore novel biomarkers in women with breast cancer, the lab generated comprehensive circulating miRNA profiles on women with breast cancer before and after surgery and compared the miRNA expression values to those found in plasma from cancer free women. They found significant differences in expression profiles between the 3 groups in our pilot dataset. They also compared the expression of miRNAs in pre- and post-operative plasma samples with miRNA levels in corresponding tissue sample women with stage I invasive ductal carcinoma. Although the results are very preliminary, they do support the hypothesis that expression levels of specific circulating miRNAs are correlated to their presence in the tumor itself.
In another ongoing research project, the lab compared the circulating miRNA profile of pre-surgical plasma in Caucasian and African American women with either ER/PR positive breast cancer or triple negative breast cancer (TNBC). Several microRNAs (miRNAs) have been associated with TNBC; however, it was unknown if miRNAs contribute to the observed disparity in TNBC progression and survival outcome between African American (AA) and Caucasian American (CA) women in the US. Our preliminary data show circulating miRNA profiles of AA and CA women with TNBC have 46 miRNAs that are differentially expressed. This suggests that although TNBC may appear clinopathologically the same in these two populations, their underlying molecular profile is not. By determining miRNA expression profiles and their respective target genes that are unique to AA or CA TNBC, we will be able to identify specific genes/pathways to explain the lower overall survival of AA women with TNBC compared to their CA counterparts and modify current treatment protocols accordingly.